HOPA Now

About HOPA Now

The landscape of hematology/oncology pharmacy continues to evolve. Join a select group of industry experts as they discuss initiatives aimed at growing and advancing the field of hematology/oncology pharmacy. Whether you are hematology/oncology pharmacist, pharmacy intern, resident, fellow, student, technician, or administrator, this informative podcast is for you.

Publisher

HOPA

Category

education · health & fitness

Language

en

Explicit

No

First episode

26 Feb 2020

Latest episode

27 Aug 2021

Latest episodes

39 episodes in the feed.

1. 

   27 Aug 2021

   [Education] Genitourinary Cancers: Top 10 Clinical Pearls

   HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer. These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course. In this episode of HOPA Now, Dr. Lisa Holle discusses genitourinary cancer clinical pearls, including bladder cancer survival benefit options such as split dose treatments, primary treatment options for early and late-stage renal cancers, bone modifying agent recommendations for patients with bone metastases and management for asymptomatic patients. In this episode you will learn: Genitourinary Cancers: Top 10 Clinical Pearls Bladder cancer survival benefit options, including split-dose treatments The relationship between vitamin B12 deficiencies and bladder resections The primary treatment of early-stage renal cancer with one exception Criteria for the treatment of stage 4 renal cancer Bone-modifying agent recommendations for renal cancer Management for asymptomatic, early-stage prostate cancer patients Relugolix as an ADT option in some prostate cancers Considerations for treatment of relapsed or refractory prostate cancer patients Dosing of bone-modifying agents used in prostate cancer patients Radiation therapy recommendations based on cancer stages Preferred chemotherapy for nonseminoma and seminoma Bleomycin pulmonary toxicity Mentioned in This Episode: HOPA (http://www.hoparx.org/) Quotes: “In early-stage renal cancer, no established role exists for adjuvant therapy except in patients with stage 3 renal cell cancer of clear cell histology and high risk for relapse.” — Dr. Lisa Holle “Bone-modifying agents are recommended for renal cell cancer patients with bone metastases.” — Dr. Lisa Holle “Early-stage prostate cancer patients have a very high rate of 10-year survival.” — Dr. Lisa Holle

2. 

   27 Aug 2021

   [Education] Lung Cancer: Top 10 Clinical Pearls

   HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer. These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course. In this episode of HOPA Now, Dr. Daniel Melzer highlights the top ten clinical pearls regarding various forms and stages of lung cancer and the treatment options for these different disease diagnoses. He also shares chemotherapy treatments and survival rates and other considerations that can help determine future therapy options in various diagnosis situations. In this episode you will learn: Lung Cancer Considerations and Treatments Stage four non-small cell lung cancer targeted therapy guidelines Diagnoses in which treatment must be an immunotherapy plus chemotherapy combination Metastatic disease considerations for first- and second-line setting situations The importance of histology when determining if a patient needs targeted therapy Chemotherapy treatment options and survival rates for stage one, two, and three cancer patients How first-line treatment for small cell lung cancer depends on staging Timing of relapse considerations to help determine future therapy options Mentioned in This Episode: HOPA (http://www.hoparx.org/) Tweetables: “There is a higher overall rate of survival in patients that receive pembrolizumab in the first-line setting.” — Daniel Melzer “In stage two and stage three patients, there is a survival benefit in receiving chemotherapy versus observation.” — Daniel Melzer “First-line treatment for small cell lung cancer depends on staging.” — Daniel Melzer

3. 

   8 Oct 2020

   [Education] Gastrointestinal Cancers Fundamentals

   HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer. These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course. In this episode of HOPA Now, Dr. Allison Baxley covers the high points of the pathology, diagnostic workup, and biology of GI cancers, including colon cancers, exocrine pancreatic cancers, upper GI cancers, gastric cancers, and hepatocellular carcinoma. She covers testing and recommendations, demographics and risk factors, the role of genetics, staging locations, and distinct variations between these various GI cancers. In this episode, you will learn: Gastrointestinal Cancers Fundamentals The basic pathophysiology and common genetic predisposition of colon cancers Recommendations for testing at various stages at colon cancers, including those with metastatic disease BRAF testing and recommendations and common patient response Considerations for diagnostic workup and staging process that may affect treatment decisions during early-stage disease An overview of exocrine pancreatic cancers origination, prognosis, staging decisions and treatment options The role of genetics in pancreatic cancers and recommendations for chemotherapy and PARP inhibitors Upper GI cancers including esophageal, gastric, and esophagogastric junction cancers and their histologics Distinct variations between the geography, demographics and risk factors of adenocarcinomas and squamous cell carcinomas in esophageal cancers Staging locations and clinical trials for EG junction tumors Specific hereditary risk factors for gastric cancer A brief overview of hepatocellular carcinoma including demographics, risk factors, and pathologic types Mentioned in This Episode: HOPA (http://www.hoparx.org/) Quotes: “All colon cancer patients should be tested for MSI and MMR status.” — Dr. Allison Baxley “In patients with early-stage disease, there are several things during the diagnostic workup and staging process that may affect treatment decisions.” — Dr. Allison Baxley “For gastric cancer specifically, there are several hereditary risk factors that put a patient at higher risk.” — Dr. Allison Baxley

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

4.8 / 5

15 ratings

Contact HOPA Now

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.